Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials
Long-term efficacy of generic antiviral drugs (tenofovir and entecavir) in suppression of viral replication in chronic hepatitis B
Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients
A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials
Concomitant use of direct-acting antivirals (DAAs) and central nervous system drugs in current chronic hepatitis C patient profile
The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness
Drug-drug interactions (DDIs) with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C; understanding the populations at risk and real-world care management
Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program
Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center
Managing hepatitis C in people who inject drugs (PWID) using the internist-addiction medicine-hepatology (IAHC) model to achieve Hep C micro-elimination
Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees
Hepatitis C reflex testing in Spain in 2019: a story of success
Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?
Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care
A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors
The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from realworld practices varies across the world
Impact of non-alcoholic fatty liver disease on cardiovascular risk in a general population Europe’s largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4)